Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ -
Tuesday, November 30, 2021:
HUTCHMED (China) Limited ("
HUTCHMED"
) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at November 30, 2021, the issued share capital of
HUTCHMED
consisted of 864,460,700 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury.
The above figure of 864,460,700 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
For illustrative purposes only, the 864,460,700 ordinary shares would be equivalent to 864,460,700 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 172,892,140 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,500 personnel across all its companies, at the center of which is a team of over 1,400 in oncology/immunology. Since inception it has advanced eleven cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries |
|
Mark Lee, Senior Vice President |
+852 2121 8200 |
Annie Cheng, Vice President |
+1 (973) 567 3786 |
|
|
Media Enquiries |
|
Americas - Brad Miles, Solebury Trout |
+1
(917)
570
7340
(Mobile)
|
Europe - Ben Atwell / Alex Shaw, FTI Consulting |
+44
20
3727
1030 / +44
7771
913
902
(Mobile) / +
44 7779 545 055 (Mobile)
|
Asia - Zhou Yi, Brunswick |
+852 97 83 6894 (Mobile) |
|
|
Nominated Advisor |
|
Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK) Limited |
+44 (20) 7886 2500 |